AbbVie Inc. $ABBV Stock: Compass Capital Management Inc. Boosts Position

Compass Capital Management Inc. grew its position in AbbVie Inc. (NYSE:ABBV) by 387.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,900 shares of the company’s stock after purchasing an additional 3,100 shares during the period. Compass Capital Management Inc.’s holdings in AbbVie were worth $1,020,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of ABBV. State Street Corp boosted its position in AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after buying an additional 1,379,232 shares during the last quarter. Fisher Asset Management LLC increased its holdings in AbbVie by 252.6% in the 3rd quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock worth $8,760,498,000 after buying an additional 23,991,451 shares during the period. Corient Private Wealth LP purchased a new position in AbbVie during the 2nd quarter worth approximately $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in AbbVie by 0.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after acquiring an additional 106,091 shares during the period. Finally, Legal & General Group Plc purchased a new stake in shares of AbbVie in the 2nd quarter valued at $2,905,952,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the transaction, the executive vice president owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

AbbVie Trading Up 0.2%

AbbVie stock opened at $295.18 on Friday. The firm has a market cap of $521.76 billion, a PE ratio of 50.81, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $302.93. The stock’s 50 day simple moving average is $275.51 and its two-hundred day simple moving average is $240.91.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The firm had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. During the same period in the previous year, the firm earned $1.86 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that AbbVie Inc. will post 13.98 EPS for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a dividend of $1.82 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a yield of 2.5%. The ex-dividend date is Friday, January 15th. AbbVie’s dividend payout ratio (DPR) is 125.30%.

Analyst Ratings Changes

ABBV has been the subject of several recent research reports. Piper Sandler raised their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Morgan Stanley boosted their target price on shares of AbbVie from $310.00 to $346.00 and gave the company an “overweight” rating in a research report on Monday, November 2nd. Barclays upped their price target on shares of AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a report on Wednesday, October 21st. UBS Group increased their price target on AbbVie from $275.00 to $295.00 and gave the stock a “neutral” rating in a research report on Monday, November 2nd. Finally, Oppenheimer increased their price target on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $297.46.

Trending Headlines about AbbVie

Here are a few of the latest headlines about ABBV:

• Positive Sentiment: AbbVie’s immunology sales grew 16.6% in the third quarter, led by Skyrizi and Rinvoq. Their momentum is helping lift sales expectations for 2026, although Humira continues to decline. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Positive Sentiment: AbbVie licensed Nxera Pharma’s EP4 agonist program for inflammatory bowel disease. The deal adds a potential pipeline asset, though its milestones depend on future development and other conditions. AbbVie Deal Altering the Investment Case for Nxera Pharma
• Negative Sentiment: EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. The sale could weigh on sentiment, though the filing did not state a reason. AbbVie EVP Sells $11,925,738.40 in Stock

AbbVie Company Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.